Natural Product (NP) Details
General Information of the NP (ID: NP8905) | |||||
---|---|---|---|---|---|
Name |
Astilbin
|
||||
Synonyms |
Astilbin; 29838-67-3; Isoastilbin; Taxifolin 3-O-rhamnoside; Neoisoastilbin; CHEBI:38200; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)chroman-4-one; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,3-[(6-deoxy-a-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; Dihydroquercitrin; 54081-48-0; CHEMBL486017; MEGxp0_000363; ACon1_000616; dihydroquercetin-3-O-alpha-LRhap; DTXSID501019948; AMY22307; HY-N0509; s3932; ZINC31156118; AKOS025402308; AC-8008; CCG-269236; MCULE-6234117773; NCGC00168909-01; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one; BS-16813; CS-0009049; W1551; C17449; Astilbin from Engelhardtia roxburghiana, >=98%; Dihydroquercetin 3-O-.alpha.-L-rhamnopyranoside; Q-100379; Q4810880; (2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-3,4-dihydro-2H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside; (2R,3R)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4H-1-benzopyran-4-one; (2R-trans)-3-((6-Deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R-trans)-; 4H-1-Benzopyran-4-one, 3-[(6-deoxy-.alpha.-L-mannopyranosyl)oxy]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-5,7-dihydroxy-, (2R,3R)-; NCGC00168909-02!(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
Click to Show/Hide
|
||||
Species Origin | Smilax glabra ... | Click to Show/Hide | |||
Smilax glabra | |||||
Disease | Osteoarthritis [ICD-11: FA00-FA05] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H22O11
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1C(C(C(C(O1)OC2C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
|
||||
InChI |
1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3/t7-,15-,17+,18+,19+,20-,21-/m0/s1
|
||||
InChIKey |
ZROGCCBNZBKLEL-MPRHSVQHSA-N
|
||||
CAS Number |
CAS 29838-67-3
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Methotrexate | Leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | STAT1 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Specific-pathogen-free, eight-week-old male DBA/1J mice, and Eight-week-old C57BL/6 mice were used in this study. | |||||
Experimental
Result(s) |
Astilbin is a valuable candidate for low-dose MTX combined therapy in RA via increasing A2AAR/adenosine system and decreasing ERK/NFKappaB/STATs signals. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Interleukin-10 (IL10) | Molecule Info | [3] | |
Tumor necrosis factor (TNF) | Molecule Info | [4] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | Cytokine-cytokine receptor interaction | |||
3 | NF-kappa B signaling pathway | |||
4 | Sphingolipid signaling pathway | |||
5 | mTOR signaling pathway | |||
6 | Apoptosis | |||
7 | TGF-beta signaling pathway | |||
8 | Osteoclast differentiation | |||
9 | Antigen processing and presentation | |||
10 | Toll-like receptor signaling pathway | |||
11 | NOD-like receptor signaling pathway | |||
12 | RIG-I-like receptor signaling pathway | |||
13 | Hematopoietic cell lineage | |||
14 | Natural killer cell mediated cytotoxicity | |||
15 | T cell receptor signaling pathway | |||
16 | Fc epsilon RI signaling pathway | |||
17 | TNF signaling pathway | |||
18 | Adipocytokine signaling pathway | |||
19 | Type II diabetes mellitus | |||
20 | Non-alcoholic fatty liver disease (NAFLD) | |||
21 | Type I diabetes mellitus | |||
22 | Alzheimer's disease | |||
23 | Amyotrophic lateral sclerosis (ALS) | |||
24 | Pertussis | |||
25 | Legionellosis | |||
26 | Leishmaniasis | |||
27 | Chagas disease (American trypanosomiasis) | |||
28 | African trypanosomiasis | |||
29 | Malaria | |||
30 | Toxoplasmosis | |||
31 | Amoebiasis | |||
32 | Tuberculosis | |||
33 | Hepatitis C | |||
34 | Hepatitis B | |||
35 | Influenza A | |||
36 | HTLV-I infection | |||
37 | Herpes simplex infection | |||
38 | Proteoglycans in cancer | |||
39 | Asthma | |||
40 | Inflammatory bowel disease (IBD) | |||
41 | Systemic lupus erythematosus | |||
42 | Rheumatoid arthritis | |||
43 | Allograft rejection | |||
44 | Graft-versus-host disease | |||
45 | Hypertrophic cardiomyopathy (HCM) | |||
46 | Dilated cardiomyopathy | |||
47 | FoxO signaling pathway | |||
48 | Jak-STAT signaling pathway | |||
49 | Intestinal immune network for IgA production | |||
50 | Staphylococcus aureus infection | |||
51 | Epstein-Barr virus infection | |||
52 | Autoimmune thyroid disease | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | IL2 Signaling Pathway | |||
3 | IL3 Signaling Pathway | |||
4 | IL4 Signaling Pathway | |||
5 | Leptin Signaling Pathway | |||
6 | RANKL Signaling Pathway | |||
7 | IL1 Signaling Pathway | |||
8 | BCR Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | Wnt signaling pathway | |||
3 | Interleukin signaling pathway | |||
Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
Pathway Interaction Database | IL27-mediated signaling events | Click to Show/Hide | ||
2 | Canonical NF-kappaB pathway | |||
3 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
4 | Angiopoietin receptor Tie2-mediated signaling | |||
5 | Signaling events mediated by HDAC Class I | |||
6 | TNF receptor signaling pathway | |||
7 | Ceramide signaling pathway | |||
8 | amb2 Integrin signaling | |||
9 | RXR and RAR heterodimerization with other nuclear receptor | |||
10 | IL23-mediated signaling events | |||
11 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
12 | Caspase Cascade in Apoptosis | |||
13 | Cellular roles of Anthrax toxin | |||
14 | Downstream signaling in naï | |||
15 | ||||
16 | Regulation of nuclear SMAD2/3 signaling | |||
17 | IL4-mediated signaling events | |||
18 | AP-1 transcription factor network | |||
Reactome | Transcriptional regulation of white adipocyte differentiation | Click to Show/Hide | ||
2 | TNFR1-induced proapoptotic signaling | |||
3 | Regulation of TNFR1 signaling | |||
4 | TNFR1-induced NFkappaB signaling pathway | |||
5 | TNFR1-mediated ceramide production | |||
6 | TNFR2 non-canonical NF-kB pathway | |||
7 | TNF signaling | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Monoamine Transport | |||
3 | SIDS Susceptibility Pathways | |||
4 | TGF Beta Signaling Pathway | |||
5 | Cytokines and Inflammatory Response | |||
6 | MAPK Signaling Pathway | |||
7 | EV release from cardiac cells and their functional effects | |||
8 | FAS pathway and Stress induction of HSP regulation | |||
9 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
10 | Cardiac Hypertrophic Response | |||
11 | Transcriptional Regulation of White Adipocyte Differentiation | |||
12 | Aryl Hydrocarbon Receptor | |||
13 | Apoptosis | |||
14 | Nanoparticle triggered regulated necrosis | |||
15 | Amyotrophic lateral sclerosis (ALS) | |||
16 | Adipogenesis | |||
17 | Allograft Rejection | |||
18 | TNF alpha Signaling Pathway | |||
19 | TWEAK Signaling Pathway | |||
20 | Extrinsic Pathway for Apoptosis | |||
21 | Folate Metabolism | |||
22 | MicroRNAs in cardiomyocyte hypertrophy | |||
23 | Vitamin B12 Metabolism | |||
24 | Selenium Micronutrient Network | |||
25 | Regulation of toll-like receptor signaling pathway | |||
26 | Matrix Metalloproteinases |